Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency;Toxicité sévère à la capécitabine liée à un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD)

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 3, 2010, Pages 218-223

  Coursier, S ^a   Martelet, S ^a   Guillermet, A ^a   Emptoz, J ^a   Villier, C ^b   Bontemps, H ^a  

^a Villefranche sur Saône Hospital   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; THYMIDINE;

ARTICLE; CASE REPORT; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; SCREENING; STOMACH CANCER; TOXICITY;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FATAL OUTCOME; FLUOROURACIL; HUMANS; INTENSIVE CARE UNITS; MALE;

EID: 77950938387     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.08.014     Document Type: Article

References (33)

1. Saif M.W., Katirtzoglou N.A., Syrigos K.N. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008, 19:447-464.
2. Walko C.M., Lindley C. Capecitabine: a review. Clin Ther 2005, 27:23-44.
3. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
4. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
5. Poole C., Gardiner J., Twelves C., Johnston P., Harper P., Cassidy J., et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002, 49:225-234.
6. Marsé H., Van Cutsem E., Grothey A., Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004, 8(Suppl 1):S16-30.
7. Aparicio T., Ducreux M., Chaussade S. 5-fluorouracil: metabolism and current indications in digestive cancer treatment. Gastroenterol Clin Biol 2002, 26:38-47.
8. Gamelin E., Boisdron-Celle M. Pharmacogénétique du métabolisme des pyrimidines. La dihydropyrimidine déshydrogénase. Oncologie 2005, 7:33-39.
9. van Kuilenburg A.B., Meinsma R., van Gennip A.H. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids 2004, 23:1371-1375.
10. Begaud B., Evreux J.C., Jouglard J., Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985, 40:111-118.
11. de Gramont A., Bosset J.F., Milan C., Rougier P., Bouche O., Etienne P., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
12. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
13. Diasio R.B., Johnson M.R. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999, 5:2672-2673.
14. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
15. Tuchman M., Stoeckeler J.S., Kiang D.T., O'Dea R.F., Ramnaraine M.L., Mirkin B.L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985 Jul 25, 313(4):245-249.
16. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988, 6:1653-1664.
17. Morel A., Boisdron-Celle M., Fey L., Soulie P., Craipeau M.C., Traore Set al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006, 5:2895-2904.
18. Johnson M.R., Wang K., Smith J.B., Heslin M.J., Diasio R.B. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000, 278:175-184.
19. Volk J., Reinke F., van Kuilenburg A.B., van Gennip A.H., Schlichting C., Ganser A., et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol 2001, 12:569-571.
20. Ahluwalia R., Freimuth R., McLeod H.L., Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003, 49:1661-1664.
21. Ezzeldin H., Okamoto Y., Johnson M.R., Diasio R.B. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002, 306:63-73.
22. Gross E., Seck K., Neubauer S., Mayr J., Hellebrand H., Ratanaphan A., et al. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 2003, 22:325-332.
23. Johnson M.R., Wang K., Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002, 8:768-774.
24. van Kuilenburg A.B., Vreken P., Abeling N.G., Bakker H.D., Meinsma R., Van Lenthe H., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999, 104:1-9.
25. Mattison L.K., Ezzeldin H., Carpenter M., Modak A., Johnson M.R., Diasio R.B. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004, 10:2652-2658.
26. Boisdron-Celle M., Remaud G., Traore S., Poirier A.L., Gamelin L., Morel A., et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007, 249:271-282.
27. Gamelin E., Delva R., Jacob J., Merrouche Y., Raoul J.L., Pezet D., et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105.
28. Maring J.G., van Kuilenburg A.B., Haasjes J., Piersma H., Groen H.J., Uges D.R., et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002, 86:1028-1033.
29. Gamelin E., Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. Crit Rev Oncol Hematol 1999, 30:71-79.
30. Gamelin E., Boisdron-Celle M., Guerin-Meyer V., Delva R., Lortholary A., Genevieve F., et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999, 17:1105.
31. Mattison L.K., Fourie J., Hirao Y., Koga T., Desmond R.A., King J.R., et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 2006, 12:549-555.
32. Mercier C., Raynal C., Dahan L., Ortiz A., Evrard A., Dupuis C., et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007, 17:841-844.
33. Ezzeldin H., Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004, 4:181-189.